• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Director Szlosek Thomas A was granted 20,023 shares, increasing direct ownership by 61% to 52,900 units (SEC Form 4)

    6/10/25 4:22:24 PM ET
    $JBI
    Building Products
    Industrials
    Get the next $JBI alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Szlosek Thomas A

    (Last) (First) (Middle)
    C/O JANUS INTERNATIONAL GROUP, INC.
    135 JANUS INTERNATIONAL BLVD.

    (Street)
    TEMPLE GA 30179

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Janus International Group, Inc. [ JBI ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/09/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 06/09/2025 A 20,023(1) A $0.00 52,900(3) D
    Common Stock 96,680 I As Joint Tenants in Common by Trusts(2)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The Reporting Person received restricted stock units ("RSUs") on June 9, 2025 having a value equal to approximately $170,000.00 based on the closing price per share of the Issuer's common stock on June 9, 2025. The RSUs will fully vest on the first anniversary of the grant date, subject to continued service on the Board of Directors, and will be settled by delivery of shares of common stock.
    2. Owned as Joint Tenants in Common by: (i) The Thomas A Szlosek 2013 Revocable Living Trust, of which the Reporting Person and the Reporting Persons spouse serve as joint trustees and the Reporting Person is the sole beneficiary, and (ii) The Sheryl E Szlosek 2013 Revocable Living Trust, of which the Reporting Person and the Reporting Persons spouse serve as joint trustees and the Reporting Persons spouse is the sole beneficiary.
    3. Includes 20,023 RSUs.
    Remarks:
    Power of Attorney is attached hereto as Exhibit 24.
    /s/ Elliot Kahler, as attorney-in-fact for Thomas A. Szlosek 06/10/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $JBI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $JBI

    DatePrice TargetRatingAnalyst
    11/4/2024$12.00 → $7.50Buy → Hold
    Jefferies
    8/12/2024Outperform → Peer Perform
    Wolfe Research
    4/15/2024$20.00Buy
    Jefferies
    7/24/2023$14.00Outperform
    Wolfe Research
    9/6/2022$15.00Market Outperform
    CJS Securities
    1/26/2022$18.00Buy
    Benchmark
    1/26/2022$18.00Buy
    The Benchmark Company
    12/9/2021$17.00Buy
    Stifel
    More analyst ratings